Serum adenosine deaminase activity is elevated in cutaneous leishmaniasis and decreases following treatment
DOI:
https://doi.org/10.54034/mic.e2712Keywords:
adenosine deaminase, cutaneous leishmaniasis, neglected diseasesAbstract
Introduction: Leishmaniases are infectious diseases caused by Leishmania protozoa, affecting millions worldwide. Diagnosis can be challenging. Accurate, non-invasive, and rapid diagnostic methods are needed. Studies suggest that adenosine deaminase activity may serve as a valuable tool. This study aimed to evaluate serum adenosine deaminase activity in patients with cutaneous leishmaniasis in an endemic area of Brazil. Methods: Fifteen patients with cutaneous leishmaniasis were evaluated before starting treatment and then monthly for up to 90 days. Enzyme activity was quantified using a commercial kit. A control group of 10 healthy participants was also included. Anthropometric, sociodemographic, and clinical data were collected. Statistical analysis included Mann-Whitney's U Test, one-way ANCOVA, Fisher's Exact Test, Fisher-Freeman-Halton's Test, and Mixed-Effects ANOVA. Results: The median serum adenosine deaminase level for the control group was 6.29 U/L (4.42-8.86). For the patient group, median levels were 12.34 U/L (9.06-18.12) at Day 0, decreasing to 8.62 U/L (7.84-11.98) by Day 90. The difference between groups at Day 0 was statistically significant (p=0.001). The difference in enzyme levels in the patient group during follow-up was also statistically significant (p=0.0255). Conclusions: Serum adenosine deaminase activity was significantly elevated in patients with cutaneous leishmaniasis and decreased significantly over time after treatment. These preliminary findings are promising, but should be interpreted with caution given the limitations of our study.
References
1. Valencia C, Arévalo J, Dujardin JC, Llanos-Cuentas A, Chappuis F, Zimic M. Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions. PLoS Negl Trop Dis. 2012;6(6):e1656. doi: 10.1371/journal.pntd.0001656
2. Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol. 2011;9(8):604–615. doi:10.1038/nrmicro2608
3. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Manual de vigilância da leishmaniose tegumentar [recurso eletrônico]. Brasília, 2017.
4. Dias DS, Ribeiro PA, Salles BCS, Santos TOS, Ramos FF, Lage DP, et al. Serological diagnosis and prognostic of tegumentary and visceral leishmaniasis using a conserved Leishmania hypothetical protein. Parasitol Int. 2018; 67(3): 344–350. doi:10.1016/j.parint.2018.02.001
5. Saini I, Joshi J, Kaur S. Unwelcome prevalence of leishmaniasis with several other infectious diseases. Int Immunopharmacol. 2022;110:109059. doi: 10.1016/j.intimp.2022.109059
6. Ministério da Saúde/SVS - Sistema de Informação de Agravos de Notificação - Sinan Net. Disponível em: http://tabnet.datasus.gov.br/cgi/deftohtm.exe?sinannet/cnv/ltamt.def
7. Sasidharan S, Saudagar P. Leishmaniasis: where are we and where are we heading? Parasitol Res. 2021; 120(5): 1541–1554. doi:10.1007/s00436-021-07139-2
8. Carvalho SH, Frézard F, Pereira NP, Moura AS, Ramos LMQC, Carvalho GB, Rocha MOC. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment. Trop Med Int Health. 2019;24(4):380–391. doi:10.1111/tmi.13210
9. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis. 2007;7(9):581–596. doi:10.1016/S1473-3099(07)70209-8
10. Bahrami F, Harandi AM, Rafati S. Biomarkers of cutaneous leishmaniasis. Front Cell Infect Microbiol. 2018;8:222. doi:10.3389/fcimb.2018.00222
11. Rai AK, Kumar P, Saini S, Thakur CP, Seth T, Mitra DK. Increased level of soluble adenosine deaminase in bone marrow of visceral leishmaniasis patients: an inverse relation with parasite load. Acta Parasitol. 2016; 61(3): 645–649. doi:10.1515/ap-2016-0087
12. Castellano LR, Filho DC, Argiro L, Dessein H, Prata A, Dessein A, et al. Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-γ production. Hum Immunol. 2009;70(6):383-390. doi: 10.1016/j.humimm.2009.01.007
13. Mukherjee S, Mukhopadhyay D, Ghosh S, Barbhuiya JN, Das NK, Chatterjee M. Decreased frequency and secretion of CD26 promotes disease progression in Indian post-kala-azar dermal leishmaniasis. J Clin Immunol. 2016;36(1):85-94. doi:10.1007/s10875-015-0215-8
14. Gakis C. Adenosine deaminase (ADA) isoenzymes ADA1 and ADA2: diagnostic and biological role. Eur Respir J. 1996;9(4):632–633. doi:10.1183/09031936.96.09040632
15. Ye Q, Yan W. Adenosine deaminase from the cerebrospinal fluid for the diagnosis of tuberculous meningitis: a meta-analysis. Trop Med Int Health. 2023;28(3):175–185. doi:10.1111/tmi.13849
16. Lee YC, Rogers JT, Rodriguez RM, Miller KD, Light RW. Adenosine deaminase levels in nontuberculous lymphocytic pleural effusions. Chest. 2001;120(2):356–361. doi:10.1378/chest.120.2.356
17. Vijayamahantesh V, Amit A, Dikhit MR, Pandey RK, Singh AK, Mishra R, et al. Elevated serum ADA activity as a marker for diagnosis and prognosis of visceral leishmaniasis and post kala-azar dermal leishmaniasis in Indian patients. PLoS One. 2016;11(5):e0154117. doi:10.1371/journal.pone.0154117
18. Erel O, Kocyigit A, Gurel MS, Bulut V, Seyrek A, Ozdemir Y. Adenosine deaminase activities in sera, lymphocytes and granulocytes in patients with cutaneous leishmaniasis. Mem Inst Oswaldo Cruz. 1998;93(4):491–494. doi: 10.1590/S0074-02761998000400014
19. Passos VMA, Barreto SM, Romanha AJ, Krettli AU, Volpini AC, Gontijo CMF, Falcão AL, Lima-Costa MF. Leishmaniose tegumentar na Região Metropolitana de Belo Horizonte: aspectos clínicos, laboratoriais, terapêuticos e evolutivos (1989-1995). Rev Soc Bras Med Trop. 2001;34(1):5–12. Portuguese. doi:10.1590/S0037-86822001000100002
20. Rocha TJM, Barbosa ACA, Santana EPC, Calheiros CML. Aspectos epidemiológicos dos casos humanos confirmados de leishmaniose tegumentar americana no Estado de Alagoas, Brasil. Rev Pan-Amaz Saúde. 2015; 6(4):49–54. doi:10.5123/S2176-62232015000400007
21. Santana GdS. Estudo da associação de micronutrientes (zinco, cobre e ferro) na infecção e/ou progressão para leishmaniose tegumentar em duas comunidades rurais do Estado da Bahia. Fiocruz Arca Repositório Institucional [Internet]. Salvador: Fundação Oswaldo Cruz; 2014. Available from: https://www.arca.fiocruz.br/handle/icict/9044
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Juan J. Milla Espino, Márcia Hueb, Rodrigo Haddad, Daiani C. Alves Haddad, Elza Ferreira Noronha
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
